Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 and ABT-333 Coadministered with Ribavirin in Adults with Genotype 1 Chronic HCV and HIV

Investigator: Anne Luetkemeyer, MD
Sponsor: AbbVie Inc.

Location(s): United States


The purpose of this study is to evaluate the safety and efficacy of ABT-450/r/ABT-267 and ABT-333 coadministered with RBV in HCV genotype 1 adults with HIV-1 coinfection.